Physician profile
Andrew Robert Baker
NPI 1427318393
$102,202.12
in general payments reported to CMS, 2019-2025
34 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $929 · 2022: $1,551 · 2023: $12K · 2024: $25K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $18K · Food and Beverage: $14K · Education: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,897.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,048.00 |
| Travel and Lodging | $18,434.40 |
| Food and Beverage | $13,820.43 |
| Education | $522.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23,333.94 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $13,977.60 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $12,786.53 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $11,374.32 | 2021-2025 | Cosentyx |
| Sun Pharmaceutical Industries INC. | $9,365.84 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $8,031.17 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $6,498.25 | 2021-2025 | Tremfya, Stelara, Simponi |
| Arcutis Biotherapeutics, INC. | $6,205.88 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,302.81 | 2022-2023 | Spevigo, Cyltezo |
| Abbvie INC. | $2,184.49 | 2021-2025 | |
| Leo Pharma INC. | $1,930.23 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $855.01 | 2021-2025 | Bimzelx, Cimzia |
| Sanofi US Services INC. | $823.00 | 2025 | |
| Dermavant Sciences, INC. | $556.83 | 2022-2024 | Vtama |
| Lilly USA, LLC | $434.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $276.66 | 2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $272.23 | 2021-2025 | Nemluvio |
| Pfizer INC. | $198.66 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $99.83 | 2024-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $96.78 | 2025 | |
| Collegium Pharmaceutical, INC. | $93.44 | 2021 | |
| Biofrontera INC. | $78.83 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $75.26 | 2025 | Sofdra |
| Amgen INC. | $65.03 | 2024 | Otezla |
| Almirall LLC | $48.07 | 2022-2025 | Seysara, Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $42.49 | 2021-2022 | |
| Genentech USA, INC. | $36.04 | 2024 | Erivedge, Xolair |
| Vyne Pharmaceuticals INC. | $33.82 | 2021 | |
| Celgene Corporation | $27.43 | 2024 | Sotyktu |
| Abbott Laboratories | $22.72 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.36 | 2024 | Siliq |
| Nabriva Therapeutics, Plc | $17.85 | 2022 | |
| Fresenius Kabi USA, LLC | $17.63 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $16.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.